Drug Profile
Research programme: bacterial infection therapeutics - Vaxdyn
Alternative Names: AcinetoVax; AppeVax; EcoVax; K-Vax; KapaVax Trivalent vaccine; P-Vax; VXD 001; VXD 002; VXD-003; VXD-004Latest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Vaxdyn
- Class Bacterial vaccines; Escherichia coli vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acinetobacter infections; Community-acquired pneumonia; Nosocomial pneumonia; Pseudomonal infections
- Research Escherichia coli infections
Most Recent Events
- 14 Jun 2023 Preclinical development for Acinetobacter-infections (Prevention) is ongoing in Spain (Parenteral) (Vaxdyn pipeline, June 2023)
- 14 Jun 2023 Early research in Escherichia coli infections in Spain (Parenteral), prior to June 2023 (Vaxdyn pipeline, June 2023)
- 14 Jun 2023 Preclinical trials in Community-acquired pneumonia (Prevention) in Spain (Parenteral)